SCHEMBL21176174

SCHEMBL21176174

CC(C)(C)OC(=O)NCCNC(=O)C(=O)[C@H]1CCC(=O)N1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP2C19 P33261 4/20 0.45
CYP2C9 P11712 3/20 0.45
CYP2D6 P10635 3/20 0.45
TSHR P16473 2/20 0.45
ALDH1A1 P00352 2/20 0.45
ALOX15 P16050 1/20 0.44
NPFFR1 Q9GZQ6 1/20 0.44
NPFFR2 Q9Y5X5 1/20 0.44
OPRL1 P41146 1/20 0.44
USP2 O75604 1/20 0.43
CYP3A4 P08684 2/20 0.43
IDO1 P14902 1/20 0.43
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21176334 0.95 TSHR (0.47) P2RX7GAAKMT2AL3MBTL1CYP2C19
SCHEMBL21176220 0.95 TSHR (0.47) P2RX7GAAKMT2AL3MBTL1CYP2C19
SCHEMBL21176246 0.95 TSHR (0.47) P2RX7GAAKMT2AL3MBTL1CYP2C19
SCHEMBL21176325 0.92 USP2 (0.50) P2RX7GAAKMT2AL3MBTL1CYP2C19
SCHEMBL21176333 0.86 DRD2 (0.48) P2RX7GAAKMT2ACYP2C19CYP2C9
SCHEMBL21183538 0.86 P2RX7 (0.50) P2RX7GAAKMT2ACYP2C19CYP2C9
SCHEMBL19974758 0.86 P2RX7 (0.52) P2RX7GAAKMT2ACYP2C19CYP2C9
SCHEMBL21176312 0.85 CYP2C19 (0.48) P2RX7GAAKMT2ACYP2C19CYP2C9
Hydrochloric Acid SCHEMBL19975340 0.85 P2RX7 (0.49) P2RX7GAAKMT2ACYP2C19CYP2C9
SCHEMBL21183595 0.85 P2RX7 (0.51) P2RX7GAAKMT2ACYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885GAA 75/4885KMT2A 4031/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C P2RX7 564/4885GAA 107/4885KMT2A 4177/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885GAA 75/4885KMT2A 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.